Bajaj Healthcare is a mid-sized, vertically integrated pharmaceutical manufacturer whose earnings base is shifting. In FY25, APIs were 83.13% of revenue and formulations 16.87%. By Q2 FY27, formulation revenue was ₹41.7 crore, about 24% of quarterly revenue, and export API plus formulations crossed ₹100 crore, close to 60% of revenue. The company still makes more than 50 APIs and sells domestically and in regulated export markets, but the growth vector is now export APIs, formulation/CDMO work, peptides and oncology. That mix shift is the central economic mechanism: domestic API is price-competitive and volatile, while management says exports and formulations carry better margins.
The Q2 FY27 result illustrates the operating leverage. Revenue rose 18.9% to ₹175.9 crore, EBITDA rose 12.2% to ₹32.1 crore, and PAT rose 26.9% to ₹14.1 crore. Gross margin was 48.3%, flat sequentially but down year on year, which management linked to West Asia disruption and freight; EBITDA margin still improved to 18.2% on product mix. For H1, revenue grew 15.1% to ₹341.5 crore, EBITDA was ₹61.7 crore at 18.1%, and PAT grew 21.1% to ₹27.8 crore. Management guides FY27 revenue and profit growth of 10-15% with an 18-20% EBITDA margin and says it is on track. H1 is ahead of that growth range, but one half does not prove the full year, especially because Q2 formulation growth was unusually strong.
The near-term earnings path has three supports. First, export API grew 28.5% in Q2 and has a regulatory pipeline: 110 DMFs filed, 12 CEPs in Europe with 8 approved and 4 under review, 17 products identified in Brazil, 17 in Korea and 3 registered in Egypt. Second, formulations are scaling from a low base, with Cenobamate launched in September through eight marketing partners; management reports repeat orders but says revenue is difficult to quantify for two years. Third, the FY29 target of ₹900-1,000 crore revenue at 18-21% EBITDA margin gives a medium-term frame. That target is an aspiration, not FY27 guidance, and it depends on new plants.
The new plant milestones are explicit. The 250 kg/annum peptide plant is scheduled for completion by 31 March 2027, with solid-phase synthesis and fermentation for pharmaceutical, nutraceutical and cosmetic peptides. Six peptide APIs are at pilot scale; management expects commercial production from Q2 and first-year revenue of ₹70-100 crore in FY29 after 6-10 months of customer approvals, with about ₹300 crore the following year. The oncology API plant is targeted to start in Q2 FY28, serving own-brand oncology and CDMO customers; management expects about ₹200 crore revenue in 2-3 years and 60-70% backward integration of the oncology portfolio, with a 10-15% margin benefit that the transcript states ambiguously. The Nashik formulation plant, acquired through Genrx, has received NCLT approval and is targeted for Q1 FY28; management sees ₹200-250 crore revenue from the unit in 2-3 years. The new R&D centre started in August with more than 80 people and capacity for 120 chemists.
Capital allocation is a step-up rather than a return of cash. FY27 capex is guided at ₹65-80 crore, up from the prior annual range, and management says it will invest ₹50-60 crore annually after FY27 to support the ₹900-1,000 crore target. The balance sheet can carry it: net worth was ₹557 crore at September 2026, debt/equity about 0.5x, and India Ratings upgraded the long-term rating to Ind-A Stable. FY27 operating cash flow is guided above ₹30 crore, but inventory is elevated because of West Asia disruption and receivable turnover, though improved from 145 to 135 days, remains a working-capital drag. The capex is therefore funded from a stronger balance sheet but with less free cash flow than the prior year.
Management delivery is only partly verifiable. The bundle contains one call, so earlier promises can be checked mainly where the analyst or management references them. FY27 guidance is stated as on track. Capex guidance has been raised. The peptide and oncology timelines have been made more explicit, and the Genrx NCLT approval has been received. But Cenobamate's prior ₹10-12 crore FY27 quantification was withdrawn as difficult for two years, and the receivable target below 110-120 days was not restated. The company has strengthened senior management with a COO, institutional sales, global API, R&D, ROW branded generics and oncology sales heads, using ESOPs and performance incentives. That is supportive but not proof of execution.
The falsifiers are concrete. A delay in peptide completion beyond 31 March 2027, or customer approvals beyond the stated 6-10 months, pushes the first ₹70-100 crore year out and weakens the FY29 target. A slip in oncology from Q2 FY28 or Nashik from Q1 FY28 defers the ₹200 crore and ₹200-250 crore revenue opportunities. A further decline in domestic API, with export API or formulations unable to offset, would pressure the 10-15% FY27 growth guidance and the 18-20% margin. A gross-margin squeeze from West Asia, freight or input costs that product mix cannot offset would hit EBITDA. Working capital is the quieter risk: inventory and 135-day receivables limit cash conversion.
The investment thesis is therefore a j-curve with operating leverage, not a commodity API recovery. The next 18-24 months are about delivering the FY27 base while commissioning the peptide, oncology and Nashik assets. If the mix shift continues and the plants start on time, the revenue base and margin structure can step up toward the FY29 aspiration. If approvals or commissioning slip, the company remains a mid-sized API manufacturer with a promising but unproven formulation and peptide pipeline. No price target or valuation judgment is implied.
companyname: Bajaj Healthcare Limited ticker: BAJAJHCARE sector: Pharmaceuticals (API, Intermediates, Finished Dosage Formulations, Nutraceuticals) Bajaj Healthcare Limited (BHL) is a vertically integrated pharmaceutical manufacturer based in Thane, Maharashtra, founded in 1993. It operates across three product categories: Active Pharmaceutical Ingredients (APIs), Finished Dosage Formulations (FDFs), and Intermediates, with supplementary manufacturing in nutraceuticals. The company operates 15 ...
Read the full report →capex, margin expansion, regulatory approval, new product segment, acquisition inorganic
FY27: management guides 10-15% revenue and profit growth and an 18-20% EBITDA margin; FY27 capex is guided at ₹65-80 crore. FY29 aim: ₹900-1,000 crore revenue with an 18-21% EBITDA margin. Peptide plant completion is targeted for 31 March 2027, oncology API commercialisation for Q2 FY28 and the Nashik formulation plant for Q1 FY28. FY27 operating cash flow is guided above ₹30 crore; after FY27, annual capex is guided at ₹50-60 crore.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Bajaj Healthcare Ltd and 4,900+ companies.
5-day free pass. No card required.